Triple Negative Breast Cancer Treatment Market Size Report 2034 | AstraZeneca, Gilead Science, Infinity Pharmaceuticals, HiberCell, Hoffmann-La Roche, Immunomedics, Merck, HiberCell, Infinity Pharmaceuticals, CytoDyn

DelveInsight's "Triple Negative Breast Cancer Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of TNBC, historical and forecasted epidemiology, as well as the TNBC market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Discover Key Insights into the Triple Negative Breast Cancer Market with DelveInsight's In-Depth Report @ Triple Negative Breast Cancer Market Size- https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Triple Negative Breast Cancer Market Report
• In February 2025, Cantargia AB initiated a clinical trial divided into two phases. Phase Ib aims to include up to 15 patients to assess the safety of nadunolimab in combination with chemotherapy (gemcitabine plus carboplatin) and determine its maximum safe dose. Phase II is expected to include 102 patients to further evaluate the treatment's efficacy.
• In February 2025, NEC Bio B.V. launched a Phase I/II multicenter, open-label, single-arm trial for triple-negative breast cancer patients receiving first-line neoadjuvant therapy. The study includes a standard-of-care PD-1 inhibitor, epirubicin/cyclophosphamide chemotherapy, and nab-paclitaxel therapy. NECVAX-NEO1 treatment may continue for an additional 24 weeks post-surgery based on the investigator's assessment of the patient's health.
• In February 2025, BioNTech SE initiated a Phase II, multi-site, randomized, open-label clinical study to evaluate the safety, efficacy, and pharmacokinetics (PK) of BNT327 at two dose levels. The study examines its combination with chemotherapeutic agents for first- and second-line treatment in patients with locally advanced or metastatic triple-negative breast cancer (mTNBC).
• In February 2025, Merck Sharp & Dohme LLC began a randomized, open-label study to assess the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) plus pembrolizumab versus treatment of physician's choice (TPC) in triple-negative breast cancer (TNBC) patients who received neoadjuvant therapy but did not achieve a pathological complete response (pCR) at surgery. The study's primary objective is to compare invasive disease-free survival (iDFS) per investigator assessment, with the hypothesis that sacituzumab tirumotecan plus pembrolizumab will demonstrate superiority over TPC.
• In February 2025, Gilead Sciences launched a clinical study to compare progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and treatment of physician's choice (TPC) in patients with previously untreated, locally advanced, inoperable, or metastatic triple-negative breast cancer. The study includes participants whose tumors do not express PD-L1, as well as those previously treated with Anti-PD-(L)1 agents in earlier settings whose tumors do express PD-L1.
• According to DelveInsight's estimates, the total incident cases of breast cancer in the 7MM were nearly 680 thousand in 2023.
• In 2023, the US accounted for the highest incident cases of TNBC with approximately 45,000 cases, which are expected to increase by 2034 at a CAGR of 1% over the forecast period from 2025 to 2034.
• In 2023, the Germany reported the highest number of incident cases of TNBC among the EU4 and the UK, with approximately 11,000 cases. France followed with nearly 10,000 cases, while Spain recorded the lowest incident cases, with nearly 5,000 cases.
• In Japan, Stage II TNBC had the highest number of cases in 2023, totaling 6,000. Additionally, there were nearly 3,000 cases in Stage I, 4,000 in Stage III, and 700 in Stage IV.
• In EU4 and the UK, BRCA1-mutated TNBC had the highest number of cases among gene mutation-specific TNBC cases in 2023, around 3,800 cases.
• In France, the highest number of cases was recorded in individuals below 45 years of age, totaling 3,200 cases in 2023.
• In 2023, Spain reported nearly 5,000 incident cases of TNBC and this figure is expected to increase by 2034 during the forecast period (2025-2034).
• In Italy, Stage II TNBC had the highest number of cases in 2023, around 4,000. Additionally, there were nearly 1,700 cases in Stage I, 2,500 in Stage III, and 500 in Stage IV.
• In 2023, Germany reported approximately 8,000 cases in Neoadjuvant/adjuvant, 5,300 cases in the 1L, 2,800 in the 2L, and 1,700 in the 3L and above treatment. This trend is expected to increase by 2034, reflecting a distribution in treatment pattern over time.
• The leading Triple Negative Breast Cancer Companies such as AstraZeneca, Gilead Science, Infinity Pharmaceuticals, HiberCell, Hoffmann-La Roche, Immunomedics, Merck, HiberCell, Infinity Pharmaceuticals, CytoDyn, and others.
• Promising Triple Negative Breast Cancer Therapies such as Abemaciclib, Bicalutamide, Durvalumab, Capivasertib, Oleclumab and others.

Stay ahead in the Triple Negative Breast Cancer Therapeutics Market with DelveInsight's Strategic Report @ Triple Negative Breast Cancer Market Outlook- https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Triple Negative Breast Cancer Epidemiology Segmentation in the 7MM
• Total Incident Cases of Breast Cancer
• Total Incident Cases of TNBC
• Gene Mutation-specific Incident Cases of TNBC
• Stage-specific Incident Cases of TNBC
• Age-specific Incident Cases of TNBC
• Line-wise Treated Incident Cases of TNBC

Download the report to understand which factors are driving Triple Negative Breast Cancer epidemiology trends @ Triple Negative Breast Cancer Prevalence- https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Triple Negative Breast Cancer Marketed Drugs
• KEYTRUDA (Pembrolizumab): Merck
KEYTRUDA (pembrolizumab) is an immunotherapy that strengthens the immune system's ability to target and destroy cancer cells. As a humanized monoclonal antibody, it blocks the PD-1 receptor, preventing its interaction with PD-L1 and PD-L2 ligands, which in turn activates T cells to attack both cancerous and healthy tissues. In TNBC, KEYTRUDA has shown efficacy in combination with chemotherapy. The KEYNOTE-355 trial assessed its use with chemotherapy agents like paclitaxel and gemcitabine in metastatic cases, while KEYNOTE-522 explored its potential in early-stage TNBC. Approved in the US, EU4 and the UK, and Japan, KEYTRUDA holds Priority Review and Breakthrough Designation (BTD).

• TRODELVY (sacitzumab govitecan-hziy): Gilead Sciences
TRODELVY (sacituzumab govitecan-hziy), an ADC targeting TROP-2, is approved for metastatic TNBC (mTNBC) patients who have received prior treatment. It delivers a topoisomerase I inhibitor directly to cancer cells, improving efficacy while reducing harm to healthy tissues. Approved in the US, EU4 and the UK, and Japan, it holds Priority Review, BTD, and Fast Track Designation (FTD). Supported by the Phase III ASCENT trial, it is also being studied with pembrolizumab in ongoing trials. The US patent expires in 2028, and the EU patent in 2029.

• TALZENNA (talazoparib): Pfizer
Talazoparib is a small-molecule PARP inhibitor that disrupts DNA repair in cancer cells by inhibiting PARP enzymes, leading to decreased tumor growth and enhanced cancer cell death. Proven effective in both BRCA1/2-mutated and wild-type breast cancers, it was approved based on the EMBRACA trial involving 431 patients with gBRCAm HER2-negative metastatic or locally advanced breast cancer. Talazoparib is administered orally and targets second-line or later therapies. It is approved in the US, EU4 and the UK, and Japan, with Priority Review Designation, and its patents are set to expire in 2029 in the US and Japan, and 2034 in Europe.

Triple Negative Breast Cancer Emerging Drugs
• DATROWAY (Datopotamab Deruxtecan): AstraZeneca/Daiichi Sankyo
Datopotamab Deruxtecan (Dato-DXd), or DATROWAY, is a precision medicine and investigational antibody drug conjugate (ADC) for TNBC, being evaluated as monotherapy and with IMFINZI in neoadjuvant, adjuvant, and metastatic settings. With Phase III data expected by 2026, it holds promise for advancing TNBC treatment across various disease stages.

• Adagloxad Simolenin: OBI Pharma
Adagloxad simolenin, a therapeutic cancer vaccine, targets the tumor-associated glycan antigen Globo H. This subcutaneous (SC) immunotherapy, a conjugate of Globo H and KLH, stimulates antibody production against cancer cells. Licensed by OBI from Merck, clinical trials at Memorial Sloan Kettering Cancer Center (MSKCC) confirmed its safety and strong immune response in metastatic breast cancer. Currently, it is being investigated in Phase III in patient with high risk, early stage Globo H+ TNBC.

• PADCEV (Enfortumab vedotin): Astellas Pharma/Pfizer
Enfortumab vedotin-ejfv is an ADC designed for targeted cancer therapy, specifically binding to Nectin-4, a protein overexpressed in tumors. This monoclonal antibody is linked to Monomethyl Auristatin E (MMAE), a microtubule-disrupting agent. Administered via IV infusion, it induces apoptosis in cancer cells. Currently, it is being evaluated in combination with pembrolizumab for TNBC and other solid tumors in 2L+ therapy, offering hope for treatment-resistant cancers.

Learn more about the FDA-approved drugs for Triple Negative Breast Cancer @ Drugs for Triple Negative Breast Cancer Treatment- https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Triple Negative Breast Cancer Market Outlook
TNBC lacks hormone receptors and HER2 expression, making it unresponsive to hormonal or HER2-targeted therapies. As a result, systemic chemotherapy has traditionally been the primary treatment, particularly for metastatic cases. The treatment approach typically begins with neoadjuvant or adjuvant therapy, followed by first-line treatment for advanced cases. If the disease progresses or does not respond adequately, second-line and subsequent therapies are considered. Immunotherapy, such as PD-1/PD-L1 inhibitors, is increasingly used in metastatic settings to enhance the immune response against the tumor.

Scope of the Triple Negative Breast Cancer Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Triple Negative Breast Cancer Companies- AstraZeneca, Gilead Science, Infinity Pharmaceuticals, HiberCell, Hoffmann-La Roche, Immunomedics, Merck, HiberCell, Infinity Pharmaceuticals, CytoDyn, and others.
• Triple Negative Breast Cancer Therapies- Abemaciclib, Bicalutamide, Durvalumab, Capivasertib, Oleclumab and others.
• Triple Negative Breast Cancer Market Dynamics: Triple Negative Breast Cancer market drivers and Triple Negative Breast Cancer market barriers
• Triple Negative Breast Cancer Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Triple Negative Breast Cancer Unmet Needs, KOL's views, Analyst's views, Triple Negative Breast Cancer Market Access and Reimbursement

To know more about Triple Negative Breast Cancer companies working in the treatment market, visit @ Triple Negative Breast Cancer Clinical Trials and Therapeutic Assessment- https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. TNBC Market Overview at a Glance
4. Executive Summary
5. Key Events
6. Disease Background and Overview
7. Epidemiology and Market Forecast Methodology
8. Epidemiology and Patient Population
9. Patient Journey
10. Marketed Therapies
11. Emerging Drug Profiles
12. TNBC: Market Analysis
13. Key Opinion Leaders' Views
14. Unmet Needs
15. SWOT Analysis
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

List of Top Selling Market Research Reports in 2025

Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
Overactive bladder syndrome market- https://www.delveinsight.com/report-store/underactive-bladder-market
Surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
Total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Indwelling catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Surgical robotic system market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
Surgical sealant market - https://www.delveinsight.com/report-store/surgical-sealant-and-adhesives-market
Novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Ventral hernia market- https://www.delveinsight.com/report-store/hernia-repair-devices-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight
Trichotillomania market- https://www.delveinsight.com/sample-request/trichotillomania-ttm-market
Medical marijuana market- https://www.delveinsight.com/blog/medical-marijuana-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.